About Precede
Precede is a company based in Boston (United States) founded in 2021 by Rehan Verjee. Precede has raised $57 million across 1 funding round from investors including Stealth. Precede offers products and services including Liquid Biopsy Platform. Precede operates in a competitive market with competitors including Guardant Health, GRAIL, Personalis, Thrive Earlier Detection and Delfi Diagnostics, among others.
- Headquarter Boston, United States
- Founders Rehan Verjee
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$57 M (USD)
in 1 rounds
-
Latest Funding Round
$57 M (USD), Series C
Oct 10, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Precede
Precede offers a comprehensive portfolio of products and services, including Liquid Biopsy Platform.
Profiles circulating chromatin from blood for gene activation analysis.
People of Precede
Unlock access to complete
Funding Insights of Precede
Precede has successfully raised a total of $57M through 1 strategic funding round. The most recent funding activity was a Series C round of $57 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Precede
Precede has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Stealth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ruggedized industrial computers and peripherals are supplied for various sectors.
|
Locked | Locked | Locked |
Investor details for Precede
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Precede
Investment portfolio details for Precede
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Precede
Detailed financials for Precede
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Precede Comparisons
Peer comparison for Precede
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Precede
Precede operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Personalis, Thrive Earlier Detection and Delfi Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
Detailed competitors of Precede
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Precede
Complete news archive for Precede
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precede
Precede was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Precede is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Rehan Verjee is the current CEO of Precede. They have also founded this company.
Precede is a funded company, having raised a total of $57M across 1 funding round to date.
Precede was established in 2021 in Boston, United States, within the biotechnology sector focused on oncology. A genome-wide liquid-biopsy platform is utilized to analyze circulating chromatin and the DNA methylome. This approach supports cancer diagnosis and aids in the creation of precision medicines. Operations emphasize diagnostic services for early detection and therapeutic development in the healthcare field.
Precede's top competitors include Guardant Health, GRAIL and Personalis.
Precede offers Liquid Biopsy Platform.
Precede has 1 investor. Key investors include Stealth.